Brought to you by 
Beaufour Ipsen, Roche developing anticancer drugs
23 Jul 2003
Executive Summary
Beaufour Ipsen licensed Roche rights to co-develop and co-market its anticancer compounds diflomotecan and BN80927. Roche's license is worldwide, except in Europe where Beaufour retains rights.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Beaufour Ipsen, Roche developing anticancer drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice